Comparative efficacy of vitamin D status in reducing the risk of bladder cancer: A systematic review and network meta-analysis

Nutrition. 2016 May;32(5):515-23. doi: 10.1016/j.nut.2015.10.023. Epub 2015 Dec 19.

Abstract

Objectives: The optimal concentration of individual vitamin D intake for preventing bladder cancer has not, to our knowledge, been defined. To evaluate the comparative efficacy of different serum 25-hydroxyvitamin D concentrations in preventing bladder cancer, we conducted a systematic search of the literature published up to April 2015.

Methods: We applied a pairwise meta-analysis to estimate direct evidence from intervention-control studies and a network meta-analysis within a Bayesian framework to combine direct and indirect evidence. Moreover, a dose-response curve was utilized to predict the optimal median serum 25-hydroxyvitamin D concentration based on the odds ratio (OR) for each quintile concentration.

Methods: Seven studies of a total of 90757 participants, including 2509 bladder cancer patients, were included. Two prospective cohort studies with 57 591 participants and 494 bladder cancer patients, and five case-control studies with 33 166 participants and 2264 bladder cancer patients. From the network meta-analysis, we observed that sufficient serum 25-hydroxyvitamin D concentrations (>75 nmol/L) were superior to all other 25-hydroxyvitamin D concentrations in decreasing the risk of bladder cancer: OR = 0.68 and 95% credible interval (CrI) 0.52 to 0.87 compared with severely deficient concentrations (<25 nmol/L); OR = 0.65 and 95% CrI 0.49 to 0.86 compared with moderately deficient concentrations (25-37.5 nmol/L); OR = 0.61 and 95% CrI 0.47 to 0.80 compared with slightly deficient concentrations (37.5-50 nmol/L); and OR = 0.65 and 95% CrI 0.48 to 0.85 compared with insufficient concentrations (50-75 nmol/L). In addition, we noted a roughly inverse correlation between bladder cancer risk and 25-hydroxyvitamin D concentrations (R(2) = 0.98, P = 0.007).

Conclusions: Ensuring sufficient serum 25-hydroxyvitamin D concentrations might play an important role in decreasing the risk of bladder cancer. The serum 25-hydroxyvitamin D concentration ≥74 nmol/L was associated with a 60% lower risk of bladder cancer incidence.

Keywords: Bladder cancer; Network meta-analysis; Serum 25-hydroxyvitamin D; Systematic review; Vitamin D.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • 25-Hydroxyvitamin D 2 / blood
  • Anticarcinogenic Agents / administration & dosage
  • Anticarcinogenic Agents / therapeutic use*
  • Bayes Theorem
  • Calcifediol / blood
  • Evidence-Based Medicine*
  • Humans
  • Network Meta-Analysis
  • Nutritional Status*
  • Risk
  • Severity of Illness Index
  • Urinary Bladder Neoplasms / blood
  • Urinary Bladder Neoplasms / epidemiology
  • Urinary Bladder Neoplasms / etiology
  • Urinary Bladder Neoplasms / prevention & control*
  • Vitamin D / administration & dosage
  • Vitamin D / therapeutic use*
  • Vitamin D Deficiency / diet therapy
  • Vitamin D Deficiency / physiopathology
  • Vitamin D Deficiency / prevention & control

Substances

  • Anticarcinogenic Agents
  • Vitamin D
  • 25-Hydroxyvitamin D 2
  • Calcifediol